These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

501 related articles for article (PubMed ID: 15371516)

  • 1. Hippocampal long-term potentiation suppressed by increased inhibition in the Ts65Dn mouse, a genetic model of Down syndrome.
    Kleschevnikov AM; Belichenko PV; Villar AJ; Epstein CJ; Malenka RC; Mobley WC
    J Neurosci; 2004 Sep; 24(37):8153-60. PubMed ID: 15371516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synaptic and cognitive abnormalities in mouse models of Down syndrome: exploring genotype-phenotype relationships.
    Belichenko PV; Kleschevnikov AM; Salehi A; Epstein CJ; Mobley WC
    J Comp Neurol; 2007 Oct; 504(4):329-45. PubMed ID: 17663443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence that increased Kcnj6 gene dose is necessary for deficits in behavior and dentate gyrus synaptic plasticity in the Ts65Dn mouse model of Down syndrome.
    Kleschevnikov AM; Yu J; Kim J; Lysenko LV; Zeng Z; Yu YE; Mobley WC
    Neurobiol Dis; 2017 Jul; 103():1-10. PubMed ID: 28342823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deficits in cognition and synaptic plasticity in a mouse model of Down syndrome ameliorated by GABAB receptor antagonists.
    Kleschevnikov AM; Belichenko PV; Faizi M; Jacobs LF; Htun K; Shamloo M; Mobley WC
    J Neurosci; 2012 Jul; 32(27):9217-27. PubMed ID: 22764230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroanatomical alterations and synaptic plasticity impairment in the perirhinal cortex of the Ts65Dn mouse model of Down syndrome.
    Roncacé V; Burattini C; Stagni F; Guidi S; Giacomini A; Emili M; Aicardi G; Bartesaghi R
    Neurobiol Dis; 2017 Oct; 106():89-100. PubMed ID: 28651891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deficits in hippocampal CA1 LTP induced by TBS but not HFS in the Ts65Dn mouse: a model of Down syndrome.
    Costa AC; Grybko MJ
    Neurosci Lett; 2005 Jul; 382(3):317-22. PubMed ID: 15925111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The functional nature of synaptic circuitry is altered in area CA3 of the hippocampus in a mouse model of Down's syndrome.
    Hanson JE; Blank M; Valenzuela RA; Garner CC; Madison DV
    J Physiol; 2007 Feb; 579(Pt 1):53-67. PubMed ID: 17158177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced Dendritic Inhibition and Impaired NMDAR Activation in a Mouse Model of Down Syndrome.
    Schulz JM; Knoflach F; Hernandez MC; Bischofberger J
    J Neurosci; 2019 Jun; 39(26):5210-5221. PubMed ID: 31000585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preservation of long-term memory and synaptic plasticity despite short-term impairments in the Tc1 mouse model of Down syndrome.
    Morice E; Andreae LC; Cooke SF; Vanes L; Fisher EM; Tybulewicz VL; Bliss TV
    Learn Mem; 2008 Jul; 15(7):492-500. PubMed ID: 18626093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The GABA
    Block A; Ahmed MM; Rueda N; Hernandez MC; Martinez-Cué C; Gardiner KJ
    Neuroscience; 2018 Feb; 372():192-212. PubMed ID: 29292072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dentate gyrus mediates cognitive function in the Ts65Dn/DnJ mouse model of Down syndrome.
    Smith GK; Kesner RP; Korenberg JR
    Hippocampus; 2014 Mar; 24(3):354-62. PubMed ID: 24339224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decreasing the Expression of GABA
    Vidal V; García-Cerro S; Martínez P; Corrales A; Lantigua S; Vidal R; Rueda N; Ozmen L; Hernández MC; Martínez-Cué C
    Mol Neurobiol; 2018 Jun; 55(6):4745-4762. PubMed ID: 28717969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased efficiency of the GABAA and GABAB receptor-mediated neurotransmission in the Ts65Dn mouse model of Down syndrome.
    Kleschevnikov AM; Belichenko PV; Gall J; George L; Nosheny R; Maloney MT; Salehi A; Mobley WC
    Neurobiol Dis; 2012 Feb; 45(2):683-91. PubMed ID: 22062771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Altered long-term potentiation in the young and old Ts65Dn mouse, a model for Down Syndrome.
    Siarey RJ; Stoll J; Rapoport SI; Galdzicki Z
    Neuropharmacology; 1997; 36(11-12):1549-54. PubMed ID: 9517425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glutamatergic transmission aberration: a major cause of behavioral deficits in a murine model of Down's syndrome.
    Kaur G; Sharma A; Xu W; Gerum S; Alldred MJ; Subbanna S; Basavarajappa BS; Pawlik M; Ohno M; Ginsberg SD; Wilson DA; Guilfoyle DN; Levy E
    J Neurosci; 2014 Apr; 34(15):5099-106. PubMed ID: 24719089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short- and long-term effects of neonatal pharmacotherapy with epigallocatechin-3-gallate on hippocampal development in the Ts65Dn mouse model of Down syndrome.
    Stagni F; Giacomini A; Emili M; Trazzi S; Guidi S; Sassi M; Ciani E; Rimondini R; Bartesaghi R
    Neuroscience; 2016 Oct; 333():277-301. PubMed ID: 27457036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NMDA receptor regulation by amyloid-beta does not account for its inhibition of LTP in rat hippocampus.
    Raymond CR; Ireland DR; Abraham WC
    Brain Res; 2003 Apr; 968(2):263-72. PubMed ID: 12663096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fragile X mice: reduced long-term potentiation and N-Methyl-D-Aspartate receptor-mediated neurotransmission in dentate gyrus.
    Yun SH; Trommer BL
    J Neurosci Res; 2011 Feb; 89(2):176-82. PubMed ID: 21162125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms underlying LTP of inhibitory synaptic transmission in the deep cerebellar nuclei.
    Ouardouz M; Sastry BR
    J Neurophysiol; 2000 Sep; 84(3):1414-21. PubMed ID: 10980014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short-term facilitation evoked during brief afferent tetani is not altered by long-term potentiation in the guinea-pig hippocampal CA1 region.
    Pananceau M; Chen H; Gustafsson B
    J Physiol; 1998 Apr; 508 ( Pt 2)(Pt 2):503-14. PubMed ID: 9508813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.